Effects of combined therapy of valsartan and rosuvastatin on patients with atrial fibrillation.

Hu, W M; Shi, Z H; Wu, D Y; Ye, S Y; Xiang, Y J; Liu, C; Chen, J C; Zeng, C L

Hu, W M; Shi, Z H; Wu, D Y; Ye, S Y; Xiang, Y J; Liu, C; Chen, J C; Zeng, C L.

Afiliação

Hu WM; Department of Cardiology, Lishui Municipal Central Hospital, Lishui, Zhejiang, China.
Shi ZH; Department of Cardiology, Lishui Municipal Central Hospital, Lishui, Zhejiang, China.
Wu DY; Department of Cardiology, Lishui Municipal Central Hospital, Lishui, Zhejiang, China.
Ye SY; Department of Cardiology, Lishui Municipal Central Hospital, Lishui, Zhejiang, China.
Xiang YJ; Department of Cardiology, Lishui Municipal Central Hospital, Lishui, Zhejiang, China.
Liu C; Department of Cardiology, Lishui Municipal Central Hospital, Lishui, Zhejiang, China.
Chen JC; Department of Cardiology, Lishui Municipal Central Hospital, Lishui, Zhejiang, China.
Zeng CL; Department of Cardiology, Lishui Municipal Central Hospital, Lishui, Zhejiang, China.

J Biol Regul Homeost Agents ; 34(6): 2215-2220, 2020.

Article em En | MEDLINE | ID: mdl-33185084

Assuntos

Fibrilação Atrial; Valsartana/uso terapêutico; Fibrilação Atrial/tratamento farmacológico; Humanos; Hipertensão; Rosuvastatina Cálcica

Palavras-chave

anti-inflammatory effects; atrial fibrillation; rosuvastatin; valsartan

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Fibrilação Atrial / Valsartana Limite: Humans Idioma: En Revista: J Biol Regul Homeost Agents Assunto da revista: BIOLOGIA / BIOQUIMICA Ano de publicação: 2020 Tipo de documento: Article País de afiliação: China

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google